Search
for

    Glossary Gonadotropin-Releasing Hormone Antagonists

    medications that block hormone signals to reduce sex hormone production

    Gonadotropin-Releasing Hormone Antagonists (GnRH antagonists) are medications that block the action of GnRH, a hormone responsible for stimulating the release of other hormones like LH and FSH from the pituitary gland. By inhibiting this pathway, GnRH antagonists can reduce the production of sex hormones such as testosterone and estrogen, making them useful in treatments for conditions like prostate cancer, endometriosis, and certain fertility issues.

    Related Terms

    Sort by

    Community Join

    6 / 6 results

      community My Estradiol Level on Finasteride

       18 upvotes 1 year ago
      Finasteride has no effect on the user's estradiol levels, and body fat may influence aromatization. The user is on testosterone replacement therapy and uses everyday injections to manage high RBC count, with plans to measure DHT, DHEA-S, and pregnenolone levels.

      community What happens if you combine dutasteride and a aromataze inhibitor?

       4 upvotes 7 years ago
      Combining dutasteride and an aromatase inhibitor may increase testosterone levels significantly, potentially enhancing athletic performance but also posing health risks like elevated blood pressure and worsened cholesterol. The user is experimenting with dutasteride, anastrozole, minoxidil, and ketoconazole shampoo to manage hair loss and estradiol levels, while monitoring side effects and hormone levels.

      community What are your thoughts on pre-finasteride blood work?

       1 upvotes 3 years ago
      The user is considering resuming finasteride after a 6-month break and is debating the necessity of extensive blood work, including hormone and health markers, to establish a baseline. They are unsure if the tests are necessary since they experienced no side effects previously.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 2 years ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.